Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Nanozymes and Hybrid Nanostructures for Cancer Therapy and Diagnosis"
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 148
Special Issue Editors
Interests: nanozymes; nanotheranostics; cancer theranostics; nanomedicine; nanoparticles for cancer diagnosis and therapy; cancer nanomedicine; hybrid nanoparticles; nanohybrids; supramolecular nanostructures; biosensors; nanosensors; fluorescent nanoparticles; bioconjugates; nanoconjugates; magnetic nanoparticles; nanoarchitectonics; biomaterials; tissue engineering
Interests: nanozymes; nanotheranostics; cancer nanomedicine; nanostructures for cancer diagnosis and therapy; hybrid nanoparticles; supramolecular nanostructures; fluorescent nanoparticles; bioconjugates; nanoconjugates; magnetic nanoparticles; nanoarchitectonics; tissue engineering
Special Issue Information
Despite extraordinary progress in cancer diagnosis and therapy in recent years, cancer remains one of the leading causes of death for humans, with nearly 20 million new cases and 10 million deaths worldwide in 2020. Regrettably, the currently available treatments mostly rely on conventional therapies involving surgery, chemotherapy, radiotherapy, and sometimes combining two or more. Thus, nanotechnology combined with medicine, termed nanomedicine, can drastically alter this scenario by offering innovative advanced multifunctional nanosystems for fighting cancer. Nanozymes, a type of novel nanomaterials with enzyme-like activity, have shown great potential to replace natural enzymes in cancer diagnosis and therapy (nanotheranostics). Since the pioneering work of Gao and Collaborators (2007) with magnetite nanoparticles demonstrating the peroxidase-like catalytic activity, nanomaterials with enzyme-like activities, including metals, metal oxide compounds, metal-carbon and other nanostructures with biocatalytic properties have been developed focused on biomedical and pharmaceutical applications. Compared with natural enzymes, nanozymes have attracted widespread interest due to their superior thermal and chemical stability, high catalytic efficiency, biosafety, relatively low cost, and easy preparation. In this view, as an emerging type of artificial biomimetic enzyme, nanozymes and hybrid nanostructures offer the advantage of amalgamating the characteristics of nanomaterials and enzymes for a breadth of potential applications and promising alternatives to circumvent the current challenges to play a pivotal role in cancer nanomedicine for diagnosis and therapy.
We are pleased to invite researchers engaged in the fascinating realm of multidisciplinary knowledge of Nanozymes and Hybrid Nanostructures to participate in a Special Issue of the journal by submitting their articles for publication in Pharmaceutics.
This Special Issue aims to gather contributions of studies and reviews with the most recent achievements of nanozymes and hybrid nanostructures in different cancer diagnosis and treatment technologies by highlighting their advantages in innovative applications. Reports investigating nanozymes and “smart” nanostructures are expected, comprising rational design, synthesis processes (“bottom-up” and “top-down”), characterization techniques (e.g., analytical and bioimaging), tumor-targeting activity, in vitro, in vivo, and clinical applications, converging to cancer diagnosis and therapy. In addition, up-to-date reviews offering a critical view of challenges, future research directions, and perspectives on using nanozymes in this rapidly developing field of cancer nanomedicine and nanotheranostics are welcome, which may help for the next breakthroughs.
In this Special Issue, original research articles and reviews are welcome.
I look forward to receiving your contributions.
Prof. Dr. Herman Sander Mansur
Dr. Alexandra Ancelmo Piscitelli Mansur
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cancer nanomedicine
- nanoformulations for cancer theranostics
- hybrid nanostructures
- tumor targeting
- smart drug delivery systems
- biocatalytic and nanocatalytic tumor therapy
- nanomaterials for multimodal cancer diagnosis and therapy